Circulating MOTS-c Peptide Predicts Heart Attack Risk and Cardiac Events
Background
Understanding and predicting outcomes in Acute Coronary Syndrome (ACS), which includes severe conditions like Acute Myocardial Infarction (AMI), is critical for improving patient care. Despite advancements, identifying reliable biomarkers to accurately predict future Major Cardiac Events (MACE) remains a significant challenge. The potential of circulating mitochondrial-derived peptides, specifically Mitochondrial Open Reading Frame of the 12S Ribosomal RNA Type-c (MOTS-c), to serve as a prognostic indicator for adverse cardiac outcomes has been largely unexplored.
Results
The study revealed that MOTS-c levels were significantly higher in Acute Coronary Syndrome (ACS) patients, showing an average increase of approximately 2.3-fold compared to healthy controls (p<0.001). Among patients with Acute Myocardial Infarction (AMI), elevated baseline MOTS-c levels were strongly associated with future Major Cardiac Events (MACE). Specifically, patients in the highest quartile of MOTS-c had a 3.1-fold increased risk of experiencing MACE within 12 months of follow-up (Hazard Ratio: 3.1; 95% CI: 2.1-4.5; p<0.0001). This predictive power remained robust even after adjusting for traditional cardiovascular risk factors, with high MOTS-c levels independently predicting MACE with an area under the receiver operating characteristic curve (AUC) of 0.82. > The most critical finding was that a specific MOTS-c threshold identified patients with an over 250% increased risk of Major Cardiac Events within the follow-up period.
Why It Matters
This groundbreaking research suggests that circulating MOTS-c could serve as a powerful new diagnostic and prognostic biomarker for Acute Coronary Syndrome and Major Cardiac Events. The ability to identify patients at higher risk for adverse cardiac outcomes could significantly impact clinical practice, allowing for earlier, more aggressive interventions and personalized treatment strategies. Ultimately, this discovery could pave the way for novel diagnostic tests and potentially even therapeutic targets to improve patient stratification and reduce the burden of heart disease. Future investigations should focus on validating these findings in larger, multi-ethnic cohorts, conducting mechanistic studies to understand MOTS-c's precise role in cardiac pathology, and exploring its potential as a therapeutic agent in cardiovascular disease.